BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Yu K, Zhong G, Shen W. Identification of a m6A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma. Cancer Cell Int 2020;20:157. [PMID: 32419773 DOI: 10.1186/s12935-020-01238-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma T, Wang X, Wang J, Liu X, Lai S, Zhang W, Meng L, Tian Z, Zhang Y. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma. Front Genet 2021;12:726369. [PMID: 34721523 DOI: 10.3389/fgene.2021.726369] [Reference Citation Analysis]
2 Huang Y, Chen S, Qin W, Wang Y, Li L, Li Q, Yuan X. A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma. Front Oncol 2020;10:580513. [PMID: 33251144 DOI: 10.3389/fonc.2020.580513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yang W, Zhou W, Zhao X, Wang X, Duan L, Li Y, Niu L, Chen J, Zhang Y, Han Y, Fan D, Hong L. Prognostic biomarkers and therapeutic targets in oral squamous cell carcinoma: a study based on cross-database analysis. Hereditas 2021;158:15. [PMID: 33892811 DOI: 10.1186/s41065-021-00181-1] [Reference Citation Analysis]
4 Shi Y, Dou Y, Zhang J, Qi J, Xin Z, Zhang M, Xiao Y, Ci W. The RNA N6-Methyladenosine Methyltransferase METTL3 Promotes the Progression of Kidney Cancer via N6-Methyladenosine-Dependent Translational Enhancement of ABCD1. Front Cell Dev Biol 2021;9:737498. [PMID: 34631715 DOI: 10.3389/fcell.2021.737498] [Reference Citation Analysis]
5 Zhu D, Liu Y, Chen J, Wang Q, Li Y, Zhu Y, Feng J, Jiang J. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03496-3] [Reference Citation Analysis]
6 Dai B, Sun F, Cai X, Li C, Liu H, Shang Y. Significance of RNA N6-Methyladenosine Regulators in the Diagnosis and Subtype Classification of Childhood Asthma Using the Gene Expression Omnibus Database. Front Genet 2021;12:634162. [PMID: 33763115 DOI: 10.3389/fgene.2021.634162] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Li H, Hu J, Yu A, Othmane B, Guo T, Liu J, Cheng C, Chen J, Zu X. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Front Oncol 2021;11:642159. [PMID: 33816290 DOI: 10.3389/fonc.2021.642159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhu F, Yang T, Yao M, Shen T, Fang C. HNRNPA2B1, as a m6A Reader, Promotes Tumorigenesis and Metastasis of Oral Squamous Cell Carcinoma. Front Oncol 2021;11:716921. [PMID: 34631545 DOI: 10.3389/fonc.2021.716921] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang Y, Hua X, Shi H, Zhang L, Xiao H, Liang C. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma. Cancer Cell Int 2021;21:680. [PMID: 34923969 DOI: 10.1186/s12935-021-02364-2] [Reference Citation Analysis]
10 Xia D, Liu Q, Yan S, Bi L. Construction of a Prognostic Model for KIRC and Identification of Drugs Sensitive to Therapies - A Comprehensive Biological Analysis Based on m6A-Related LncRNAs. Front Oncol 2022;12:895315. [PMID: 35719976 DOI: 10.3389/fonc.2022.895315] [Reference Citation Analysis]
11 Fang J, Hu M, Sun Y, Zhou S, Li H. Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma. DNA Cell Biol 2020. [PMID: 33085515 DOI: 10.1089/dna.2020.5767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
12 Guan Q, Lin H, Miao L, Guo H, Chen Y, Zhuo Z, He J. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J Hematol Oncol 2022;15:13. [PMID: 35115038 DOI: 10.1186/s13045-022-01231-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Liu J, Wang Y, Yin J, Yang Y, Geng R, Zhong Z, Ni S, Liu W, Du M, Yu H, Bai J, Cao S. Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy. Journal of Oncology 2022;2022:1-21. [DOI: 10.1155/2022/3477148] [Reference Citation Analysis]
14 Zhang SY, Zhang SW, Zhang T, Fan XN, Meng J. Recent advances in functional annotation and prediction of the epitranscriptome. Comput Struct Biotechnol J 2021;19:3015-26. [PMID: 34136099 DOI: 10.1016/j.csbj.2021.05.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Guimarães-Teixeira C, Barros-Silva D, Lobo J, Soares-Fernandes D, Constâncio V, Leite-Silva P, Silva-Santos R, Braga I, Henrique R, Miranda-Gonçalves V, Jerónimo C. Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. J Pers Med 2021;11:996. [PMID: 34683137 DOI: 10.3390/jpm11100996] [Reference Citation Analysis]
16 Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol 2021;19:241. [PMID: 34389000 DOI: 10.1186/s12957-021-02354-8] [Reference Citation Analysis]
17 Chen X, Zhou X, Wang X. m6A binding protein YTHDF2 in cancer. Exp Hematol Oncol 2022;11:21. [PMID: 35382893 DOI: 10.1186/s40164-022-00269-y] [Reference Citation Analysis]
18 Zhang L, Luo X, Qiao S. METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma. Br J Cancer. [DOI: 10.1038/s41416-022-01757-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ma T, Wang J, Liu X, Zhang W, Meng L, Zhang Y. m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma. Front Genet 2022;13:864549. [PMID: 35528542 DOI: 10.3389/fgene.2022.864549] [Reference Citation Analysis]
20 Liao Y, Han P, Zhang Y, Ni B. Physio-pathological effects of m6A modification and its potential contribution to melanoma. Clin Transl Oncol 2021. [PMID: 34105069 DOI: 10.1007/s12094-021-02644-3] [Reference Citation Analysis]
21 Cai Y, Feng R, Lu T, Chen X, Zhou X, Wang X. Novel insights into the m6A-RNA methyltransferase METTL3 in cancer. Biomark Res 2021;9:27. [PMID: 33879256 DOI: 10.1186/s40364-021-00278-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li X, Hou L, Zhang L, Zhang L, Wang D, Wang Z, Wen M, Yang X. OAS3 is a Co-Immune Biomarker Associated With Tumour Microenvironment, Disease Staging, Prognosis, and Treatment Response in Multiple Cancer Types. Front Cell Dev Biol 2022;10:815480. [DOI: 10.3389/fcell.2022.815480] [Reference Citation Analysis]
23 Dai F, Wu Y, Lu Y, An C, Zheng X, Dai L, Guo Y, Zhang L, Li H, Xu W, Gao W. Crosstalk between RNA m6A Modification and Non-coding RNA Contributes to Cancer Growth and Progression. Mol Ther Nucleic Acids 2020;22:62-71. [PMID: 32911345 DOI: 10.1016/j.omtn.2020.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
24 Hu Y, Zhao X. Role of m6A in osteoporosis, arthritis and osteosarcoma (Review). Exp Ther Med 2021;22:926. [PMID: 34306195 DOI: 10.3892/etm.2021.10358] [Reference Citation Analysis]